Table 2.

Clinical characteristics and endocrine treatment history in patients with confirmed ESR1-mutant cfDNA, brain or bone metastases

Clinical characteristicsEndocrine therapy before mutation analysisEndocrine therapy after mutation analysis
IDSpecimenDetected ESR1 mutationsStage at DxER StatusADJ hormonal therapyADJ hormonal therapy duration (months)Number of therapiesCumulative Exposure (months)Endocrine therapyNumber of therapiesCumu-lative exposure (months)Endo-crine therapy
CF4acfDNAY537C/S, D538GIIB+SERM5323AI, SERMNoNoNo
CF8acfDNAD538GIIB+AI13147SERD25AI, SERM
CF14acfDNA/soft tissueY537SIV+No0425AI, SERM, SERD12AI, SERM, SERD
CF16cfDNA/liverD538G0+No0435AI, SERM, SERD14AI
CF23cfDNAD538GIV+No0342AI, SERD17SERM
CF27acfDNAD538GIV+No0737AI, SERM, SERDNoNoNo
BR11BrainD538G0+No0447AI, SERM, SERD17SERM
BM14/CF28cfDNA/boneD538GIIA+AI7229AI, SERD14AI
BR19BrainD538GNKNKNKNKNKNKNKNKNKNK
BR17BrainY537S, D538GNKNKNKNKNKNKNKNKNKNK

Abbreviations: ADJ, adjuvant; AI, aromatase inhibitor; Dx, diagnosis; NK, not known; SERD, selective estrogen receptor downregulator; SERM, selective estrogen receptor modulator.

  • aPatient is deceased.